
CryoPort, Inc. (NASDAQ:CYRX – Free Report) – Equities research analysts at KeyCorp issued their FY2026 earnings estimates for shares of CryoPort in a note issued to investors on Thursday, November 5th. KeyCorp analyst P. Knight expects that the company will earn ($0.88) per share for the year. KeyCorp currently has an “Overweight” rating and a $20.00 target price on the stock. The consensus estimate for CryoPort’s current full-year earnings is ($0.88) per share. KeyCorp also issued estimates for CryoPort’s Q4 2026 earnings at ($0.17) EPS and FY2027 earnings at ($0.60) EPS.
CryoPort (NASDAQ:CYRX – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.07). CryoPort had a negative net margin of 21.46% and a negative return on equity of 8.28%. The firm had revenue of $50.22 million during the quarter, compared to analysts’ expectations of $48.66 million.
Other equities analysts have also issued reports about the company. BTIG Research upped their target price on CryoPort from $25.00 to $26.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Roth Capital reaffirmed a “buy” rating and set a $21.00 price target on shares of CryoPort in a research report on Friday, August 7th. Weiss Ratings upgraded CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, October 8th. Needham & Company LLC raised their target price on CryoPort from $19.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 6th. Finally, Guggenheim lifted their target price on CryoPort from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.69.
Get Our Latest Research Report on CryoPort
CryoPort Stock Down 0.5%
CryoPort stock opened at $19.80 on Monday. CryoPort has a 52 week low of $7.61 and a 52 week high of $21.78. The company’s 50 day moving average price is $17.51 and its two-hundred day moving average price is $13.75. The stock has a market cap of $1.00 billion, a P/E ratio of -20.41 and a beta of 1.89.
Hedge Funds Weigh In On CryoPort
Institutional investors and hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP purchased a new stake in CryoPort in the second quarter worth $8,398,000. Roubaix Capital LLC raised its stake in shares of CryoPort by 12.4% in the third quarter. Roubaix Capital LLC now owns 454,926 shares of the company’s stock valued at $7,916,000 after buying an additional 50,148 shares during the period. Royce & Associates LP purchased a new position in shares of CryoPort during the 3rd quarter valued at $7,073,000. Russell Investments Group Ltd. lifted its position in shares of CryoPort by 376.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 399,047 shares of the company’s stock valued at $6,943,000 after buying an additional 315,343 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its position in shares of CryoPort by 685.1% during the 2nd quarter. Squarepoint Ops LLC now owns 368,424 shares of the company’s stock valued at $5,784,000 after buying an additional 321,497 shares during the last quarter. 92.90% of the stock is owned by institutional investors.
Insider Transactions at CryoPort
In related news, Director Daniel Hancock sold 74,379 shares of CryoPort stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $20.21, for a total value of $1,503,199.59. Following the sale, the director owned 69,052 shares of the company’s stock, valued at approximately $1,395,540.92. The trade was a 51.86% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark W. Sawicki sold 10,000 shares of CryoPort stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $19.93, for a total transaction of $199,300.00. Following the completion of the sale, the insider directly owned 92,356 shares in the company, valued at $1,840,655.08. This trade represents a 9.77% decrease in their position. The SEC filing for this sale provides additional information. 9.50% of the stock is owned by insiders.
CryoPort Company Profile
Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company’s services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.
Recommended Stories
- Five stocks we like better than CryoPort
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.
